Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) and its collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology’s (ASN) Kidney Week 2019 taking place this week in Washington, DC.
“We believe that free fatty acid receptors represent promising targets for the development of small molecules in the treatment of inflammatory and fibrosis-related kidney diseases, and our preclinical efforts presented at Kidney Week 2019 continue to support our continued development in kidney disease,” Kenneth Galbraith, CEO, said in a statement.
“We look forward to reporting further progress in this therapeutic category as we nominate a drug candidate from our small molecule compound library to continue our development efforts,” he added.
The company made two oral presentations focused on fatty acid receptors, GPR40/GPR84, as promising targets in kidney fibrosis and a novel preclinical compound, PBI-4610, discovered by Liminal.
